Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity

S. L. Collins, R. M. Gerdes, C. D. Addario, Sari E Izenwasser

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

To better understand the influence of κ-opioid agonists on the effects of cocaine, rats were treated with daily injections of the selective κ-opioid agonist U-69593 or bremazocine. In combination with 10mg/kg cocaine, both compounds, at a dose of 0.32 mg/kg, greatly diminished locomotor activity, and these effects were maintained over a period of 5 days. In addition, the response to a challenge injection of 10mg/kg cocaine several days after the end of κ-opioid agonist treatment with or without cocaine was markedly reduced. When naltrexone was given in combination with U-69593, it blocked the reduction in cocaine-induced locomotor activity after U-69593 treatment alone. However, a single injection of either κ-opioid agonist alone had no effect on cocaine-induced locomotion several days later (i.e. no long-term effects), suggesting that multiple injections of the κ-opioid agonist are needed to reduce the locomotor activating effects of cocaine other than acutely. In addition, treatment with the κ-opioid agonist U-69593 (0.32 mg/kg) over a 5-day period decreased dopamine transporter densities in the caudate putamen, and this was also blocked by co-administration of naltrexone.

Original languageEnglish
Pages (from-to)237-245
Number of pages9
JournalBehavioural Pharmacology
Volume12
Issue number4
StatePublished - Aug 20 2001

Fingerprint

Dopamine Agonists
Locomotion
Cocaine
Opioid Analgesics
Naltrexone
Injections
Dopamine Plasma Membrane Transport Proteins
Putamen
Therapeutics
U 69593

Keywords

  • κ-opioid
  • Cocaine
  • Dopamine transporter
  • Locomotor activity
  • Rat
  • Sensitization

ASJC Scopus subject areas

  • Pharmacology
  • Neuroscience(all)

Cite this

Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity. / Collins, S. L.; Gerdes, R. M.; Addario, C. D.; Izenwasser, Sari E.

In: Behavioural Pharmacology, Vol. 12, No. 4, 20.08.2001, p. 237-245.

Research output: Contribution to journalArticle

Collins, S. L. ; Gerdes, R. M. ; Addario, C. D. ; Izenwasser, Sari E. / Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity. In: Behavioural Pharmacology. 2001 ; Vol. 12, No. 4. pp. 237-245.
@article{e69dfe5058234e1ea4ad046e0244d62c,
title = "Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity",
abstract = "To better understand the influence of κ-opioid agonists on the effects of cocaine, rats were treated with daily injections of the selective κ-opioid agonist U-69593 or bremazocine. In combination with 10mg/kg cocaine, both compounds, at a dose of 0.32 mg/kg, greatly diminished locomotor activity, and these effects were maintained over a period of 5 days. In addition, the response to a challenge injection of 10mg/kg cocaine several days after the end of κ-opioid agonist treatment with or without cocaine was markedly reduced. When naltrexone was given in combination with U-69593, it blocked the reduction in cocaine-induced locomotor activity after U-69593 treatment alone. However, a single injection of either κ-opioid agonist alone had no effect on cocaine-induced locomotion several days later (i.e. no long-term effects), suggesting that multiple injections of the κ-opioid agonist are needed to reduce the locomotor activating effects of cocaine other than acutely. In addition, treatment with the κ-opioid agonist U-69593 (0.32 mg/kg) over a 5-day period decreased dopamine transporter densities in the caudate putamen, and this was also blocked by co-administration of naltrexone.",
keywords = "κ-opioid, Cocaine, Dopamine transporter, Locomotor activity, Rat, Sensitization",
author = "Collins, {S. L.} and Gerdes, {R. M.} and Addario, {C. D.} and Izenwasser, {Sari E}",
year = "2001",
month = "8",
day = "20",
language = "English",
volume = "12",
pages = "237--245",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity

AU - Collins, S. L.

AU - Gerdes, R. M.

AU - Addario, C. D.

AU - Izenwasser, Sari E

PY - 2001/8/20

Y1 - 2001/8/20

N2 - To better understand the influence of κ-opioid agonists on the effects of cocaine, rats were treated with daily injections of the selective κ-opioid agonist U-69593 or bremazocine. In combination with 10mg/kg cocaine, both compounds, at a dose of 0.32 mg/kg, greatly diminished locomotor activity, and these effects were maintained over a period of 5 days. In addition, the response to a challenge injection of 10mg/kg cocaine several days after the end of κ-opioid agonist treatment with or without cocaine was markedly reduced. When naltrexone was given in combination with U-69593, it blocked the reduction in cocaine-induced locomotor activity after U-69593 treatment alone. However, a single injection of either κ-opioid agonist alone had no effect on cocaine-induced locomotion several days later (i.e. no long-term effects), suggesting that multiple injections of the κ-opioid agonist are needed to reduce the locomotor activating effects of cocaine other than acutely. In addition, treatment with the κ-opioid agonist U-69593 (0.32 mg/kg) over a 5-day period decreased dopamine transporter densities in the caudate putamen, and this was also blocked by co-administration of naltrexone.

AB - To better understand the influence of κ-opioid agonists on the effects of cocaine, rats were treated with daily injections of the selective κ-opioid agonist U-69593 or bremazocine. In combination with 10mg/kg cocaine, both compounds, at a dose of 0.32 mg/kg, greatly diminished locomotor activity, and these effects were maintained over a period of 5 days. In addition, the response to a challenge injection of 10mg/kg cocaine several days after the end of κ-opioid agonist treatment with or without cocaine was markedly reduced. When naltrexone was given in combination with U-69593, it blocked the reduction in cocaine-induced locomotor activity after U-69593 treatment alone. However, a single injection of either κ-opioid agonist alone had no effect on cocaine-induced locomotion several days later (i.e. no long-term effects), suggesting that multiple injections of the κ-opioid agonist are needed to reduce the locomotor activating effects of cocaine other than acutely. In addition, treatment with the κ-opioid agonist U-69593 (0.32 mg/kg) over a 5-day period decreased dopamine transporter densities in the caudate putamen, and this was also blocked by co-administration of naltrexone.

KW - κ-opioid

KW - Cocaine

KW - Dopamine transporter

KW - Locomotor activity

KW - Rat

KW - Sensitization

UR - http://www.scopus.com/inward/record.url?scp=0034897489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034897489&partnerID=8YFLogxK

M3 - Article

C2 - 11548109

AN - SCOPUS:0034897489

VL - 12

SP - 237

EP - 245

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 4

ER -